Target PACT Target background The Interferon-inducible double stranded RNA-dependent protein kinase activator, also known as PKR-associated protein X (RAX in mouse) or PACT (in human) is a cellular protein that heterodimerizes with PKR through its double-stranded RNA binding proteins (dsRBDs). PKR is an interferon (IFN)-induced serine-threonine protein kinase that plays a central role in IFN's antiviral and antiproliferative activities. In the absence of viral infections, PACT activates PKR in response to diverse stress signals as serum starvation and treatments with arsenite or peroxide, resulting in the induction of the apoptotic cascade. PACT is expressed in most cell types at a very low abundance, and overexpression of PACT causes PKR activation, leading to eIF2α phosphorylation. PACT has been shown to interact with another DRBM-containing protein, TRBP (TAR RNA binding protein), and form a triple complex with Dicer to facilitate the production of siRNA. Target alias Interferon-inducible double stranded RNA-dependent protein kinase activator A Specificity The antibody recognizes the human PACT and the mouse homologous RAX. Clone ID --- Preservative None Format Immunogen affinity purified, stored in PBS pH7.4 and lyophilized. Recommend starting dilution If reconstituted with deionized water in 50 µl: IP: 10µg, WB: 1:1000 – 1:3000, IF: 1:500. Optimal dilution has to be determined by the user. Limitations Research Use Only Storage Lyophilized antibodies can be kept at 4ºC for up to 3 months and should be kept at -20ºC for long-term storage (2 years). To avoid freeze-thaw cycles, reconstituted antibodies should be aliquoted before freezing for long-term (1 year) storage (-80ºC) or kept at 4ºC for short-term usage (2 months). For maximum recovery of product, centrifuge the original vial prior to removing the cap. Further dilutions can be made with the assay buffer. After the maximum long-term storage period (2 years lyophilized or 1 year reconstituted) antibodies should be tested in your assay with a standard sample to verify if you have noticed any decrease in their efficacy. To limit antibody loss or degradation, BSA (final concentration 1%) and sodium azide (final concentration 0.02%) can be added to the suggested first dilution. It is important to first verify if those preservatives are compatible with your assay. References